Members Across 16 States Implement a Management Services Organization to Further Its Mission to Improve Cancer Care Outcomes. https://www.newswire.com/news/qcca-launches-iq-oncology-to-further-develop-nationally-integrated-20853122
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer https://jamanetwork.com/journals/jamaoncology/fullarticle/2683625
QCCA Welcomes Stockton Hematology Oncology Medical Group! Stockton Hematology Oncology was established in 1991 to provide comprehensive care for patients diagnosed with cancer and blood… QCCA Welcomes Stockton Hematology Oncology Medical Group!
QCCA Welcomes Essex Oncology of North Jersey to its member practices! Essex Oncology is a select group of cancer specialists with a common vision: to… QCCA Welcomes Essex Oncology!
Read more here: https://www.newswire.com/news/qcca-evolves-to-become-the-first-national-clinically-integrated-20348126
Take a moment to read this interesting article detailing the journey or Dr. Tony Blau and Dr. Sibel Blau during Tony’s battle with multiple myeloma.
Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies. Liu J, Halloran JT, Bilmes JA, Daza RM, Lee C, Mahen EM, Prunkard… Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies.
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3… Buparlisib plus fulvestrant in postmenopausal women
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Kim… Ipatasertib plus paclitaxel versus placebo plus paclitaxel
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.… Phase 1/2 trial of ublituximab